Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
Lazertinib Lazcluze 80mg, 240mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2024 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Ponatinib Iclusig 45 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Cyclophosphamide Cyclophosphamide oral 50 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Sunitinib malate Sutent 37.5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.